NovoCure (NVCR) Cash from Financing Activities (2014 - 2026)

NovoCure (NVCR) has reported Cash from Financing Activities for 13 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.

• Quarterly Cash from Financing Activities rose 90.53% year-over-year to $4.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$454.6 million (down 4463.13% YoY) and the FY2025 annual result came in at -$451.3 million, down 599.74% from the prior year.
• Cash from Financing Activities improved to $4.5 million in Q2 2026 per NVCR's latest filing, from -$166000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for NVCR reached as high as $100.5 million in Q3 2025 and fell as low as -$559.5 million in Q4 2025.
• A 5-year average of -$18.1 million and a median of $3.3 million in 2022 frame the typical range for Cash from Financing Activities.
• The largest YoY upside for Cash from Financing Activities was 100417.0% in 2025 against a maximum downside of 20937.77% in 2025.
• Year by year, Cash from Financing Activities stood at $3.4 million in 2022, then tumbled by 43.99% to $1.9 million in 2023, then surged by 40.58% to $2.7 million in 2024, then slumped by 20937.77% to -$559.5 million in 2025, then jumped by 100.81% to $4.5 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $4.5 million, -$166000.0, and -$559.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.